Natural Product (NP) Details
General Information of the NP (ID: NP5891) | |||||
---|---|---|---|---|---|
Name |
Pristimerin
|
||||
Synonyms |
Celastrol-methylether; Pristimerine; GNF-PF-476; UNII-28ZK7PR57S; CHEBI:8416; Celastrol methyl ester; 28ZK7PR57S; MFCD01711331; methyl (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylate; (9b,13a,14b,20a)-3-Hydroxy-9,13-dimethyl-2-oxo-24,25,26 -trinoroleana-1(10),3,5,7-tertraen-29-oic acid methyl ester; C30H40O4; methyl (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate; Spectrum_001558; SpecPlus_000649; Spectrum2_000546; Spectrum3_001651; Spectrum4_001681; Spectrum5_000322; 24-Nor-D:A-friedooleana-1(10),3,5,7-tetraen-29-oic acid, 3-hydroxy-2-oxo-, methyl ester; SCHEMBL15020; BSPBio_003401; KBioGR_001942; KBioSS_002038; CHEMBL54804; DivK1c_006745; SPECTRUM1504181; SPBio_000591; MEGxp0_000269; DTXSID5044027; ACon0_000836; KBio1_001689; KBio2_002038; KBio2_004606; KBio2_007174; KBio3_002621; HY-N1937; ZINC4097723; BDBM50481947; CCG-38723; s9404; AKOS032960306; CS-6257; SDCCGMLS-0066814.P001; NCGC00178090-01; NCGC00178090-03; B7488; X1210; C08633; Q-100112; Q27108073; (9?,13?,14?,20?)-3-Hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid methyl ester; D:A-Friedo-24-noroleana-1(10),3,5,7-tetraen-29-oic acid, 3-hydroxy-2-oxo-, methyl ester, (20alpha)- (9CI)
Click to Show/Hide
|
||||
Species Origin | Pristimera indica ... | Click to Show/Hide | |||
Pristimera indica | |||||
Primula elatior | |||||
Maytenus canariensis | |||||
Disease | Colorectal cancer [ICD-11: 2B91] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C30H40O4
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1=C(C(=O)C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C(=O)OC)C)C)C)C)O
|
||||
InChI |
1S/C30H40O4/c1-18-19-8-9-22-28(4,20(19)16-21(31)24(18)32)13-15-30(6)23-17-27(3,25(33)34-7)11-10-26(23,2)12-14-29(22,30)5/h8-9,16,23,32H,10-15,17H2,1-7H3/t23-,26-,27-,28+,29-,30+/m1/s1
|
||||
InChIKey |
JFACETXYABVHFD-WXPPGMDDSA-N
|
||||
CAS Number |
CAS 1258-84-0
|
||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | CHK1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | TP53BP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | AsPC-1 | CVCL_0152 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
BxPC-3 | CVCL_0186 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Stress-activated protein kinase JNK1 (JNK1) | Molecule Info | [3] | |
Stress-activated protein kinase JNK2 (JNK2) | Molecule Info | [3] | ||
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | ErbB signaling pathway | |||
3 | Ras signaling pathway | |||
4 | cAMP signaling pathway | |||
5 | FoxO signaling pathway | |||
6 | Sphingolipid signaling pathway | |||
7 | Protein processing in endoplasmic reticulum | |||
8 | Wnt signaling pathway | |||
9 | Osteoclast differentiation | |||
10 | Focal adhesion | |||
11 | Toll-like receptor signaling pathway | |||
12 | NOD-like receptor signaling pathway | |||
13 | RIG-I-like receptor signaling pathway | |||
14 | Fc epsilon RI signaling pathway | |||
15 | TNF signaling pathway | |||
16 | Neurotrophin signaling pathway | |||
17 | Retrograde endocannabinoid signaling | |||
18 | Dopaminergic synapse | |||
19 | Inflammatory mediator regulation of TRP channels | |||
20 | Insulin signaling pathway | |||
21 | GnRH signaling pathway | |||
22 | Progesterone-mediated oocyte maturation | |||
23 | Prolactin signaling pathway | |||
24 | Adipocytokine signaling pathway | |||
25 | Type II diabetes mellitus | |||
26 | Non-alcoholic fatty liver disease (NAFLD) | |||
27 | Epithelial cell signaling in Helicobacter pylori infection | |||
28 | Shigellosis | |||
29 | Salmonella infection | |||
30 | Pertussis | |||
31 | Chagas disease (American trypanosomiasis) | |||
32 | Toxoplasmosis | |||
33 | Tuberculosis | |||
34 | Hepatitis C | |||
35 | Hepatitis B | |||
36 | Influenza A | |||
37 | HTLV-I infection | |||
38 | Herpes simplex infection | |||
39 | Epstein-Barr virus infection | |||
40 | Pathways in cancer | |||
41 | Colorectal cancer | |||
42 | Pancreatic cancer | |||
43 | Choline metabolism in cancer | |||
44 | T cell receptor signaling pathway | |||
NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
2 | TNFalpha Signaling Pathway | |||
Panther Pathway | Alzheimer disease-amyloid secretase pathway | Click to Show/Hide | ||
2 | Angiogenesis | |||
3 | Apoptosis signaling pathway | |||
4 | B cell activation | |||
5 | FAS signaling pathway | |||
6 | Integrin signalling pathway | |||
7 | Interferon-gamma signaling pathway | |||
8 | Oxidative stress response | |||
9 | PDGF signaling pathway | |||
10 | Parkinson disease | |||
11 | TGF-beta signaling pathway | |||
12 | T cell activation | |||
13 | Toll receptor signaling pathway | |||
14 | Ras Pathway | |||
15 | CCKR signaling map ST | |||
16 | Huntington disease | |||
Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
3 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
2 | Endothelins | |||
3 | BCR signaling pathway | |||
4 | RhoA signaling pathway | |||
5 | Noncanonical Wnt signaling pathway | |||
6 | CD40/CD40L signaling | |||
7 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
8 | Osteopontin-mediated events | |||
9 | Reelin signaling pathway | |||
10 | TRAIL signaling pathway | |||
11 | CDC42 signaling events | |||
12 | Signaling events regulated by Ret tyrosine kinase | |||
13 | Angiopoietin receptor Tie2-mediated signaling | |||
14 | FAS (CD95) signaling pathway | |||
15 | IL1-mediated signaling events | |||
16 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
17 | Glucocorticoid receptor regulatory network | |||
18 | IL2-mediated signaling events | |||
19 | Rapid glucocorticoid signaling | |||
20 | FoxO family signaling | |||
21 | Ceramide signaling pathway | |||
22 | Regulation of Androgen receptor activity | |||
23 | p75(NTR)-mediated signaling | |||
24 | ErbB1 downstream signaling | |||
25 | ATF-2 transcription factor network | |||
26 | ErbB2/ErbB3 signaling events | |||
27 | PDGFR-beta signaling pathway | |||
28 | JNK signaling in the CD4+ TCR pathway | |||
29 | Nephrin/Neph1 signaling in the kidney podocyte | |||
30 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
31 | Retinoic acid receptors-mediated signaling | |||
32 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
33 | EPO signaling pathway | |||
34 | Syndecan-2-mediated signaling events | |||
35 | Ephrin B reverse signaling | |||
36 | p53 pathway | |||
37 | N-cadherin signaling events | |||
38 | S1P2 pathway | |||
39 | Downstream signaling in naï | |||
40 | ||||
41 | RAC1 signaling pathway | |||
42 | Signaling events mediated by focal adhesion kinase | |||
43 | Glypican 3 network | |||
44 | IL12 signaling mediated by STAT4 | |||
45 | Regulation of retinoblastoma protein | |||
Reactome | NRAGE signals death through JNK | Click to Show/Hide | ||
2 | NRIF signals cell death from the nucleus | |||
3 | Oxidative Stress Induced Senescence | |||
4 | FCERI mediated MAPK activation | |||
5 | DSCAM interactions | |||
6 | JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | |||
7 | Activation of the AP-1 family of transcription factors | |||
8 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | DNA Damage Response (only ATM dependent) | |||
3 | TCR Signaling Pathway | |||
4 | ErbB Signaling Pathway | |||
5 | Insulin Signaling | |||
6 | EGF/EGFR Signaling Pathway | |||
7 | MAPK Signaling Pathway | |||
8 | TGF beta Signaling Pathway | |||
9 | FAS pathway and Stress induction of HSP regulation | |||
10 | Signaling of Hepatocyte Growth Factor Receptor | |||
11 | Kit receptor signaling pathway | |||
12 | Transcriptional activation by NRF2 | |||
13 | NLR Proteins | |||
14 | IL-3 Signaling Pathway | |||
15 | Cardiac Hypertrophic Response | |||
16 | Nanoparticle-mediated activation of receptor signaling | |||
17 | Structural Pathway of Interleukin 1 (IL-1) | |||
18 | EBV LMP1 signaling | |||
19 | JAK/STAT | |||
20 | PDGF Pathway | |||
21 | Nanoparticle triggered regulated necrosis | |||
22 | BDNF signaling pathway | |||
23 | Integrated Pancreatic Cancer Pathway | |||
24 | Oncostatin M Signaling Pathway | |||
25 | Corticotropin-releasing hormone | |||
26 | AGE/RAGE pathway | |||
27 | TNF alpha Signaling Pathway | |||
28 | B Cell Receptor Signaling Pathway | |||
29 | Prostate Cancer | |||
30 | TSLP Signaling Pathway | |||
31 | TWEAK Signaling Pathway | |||
32 | Leptin signaling pathway | |||
33 | RANKL/RANK Signaling Pathway | |||
34 | Signalling by NGF | |||
35 | IL-1 signaling pathway | |||
36 | Intrinsic Pathway for Apoptosis | |||
37 | DSCAM interactions | |||
38 | Apoptosis Modulation and Signaling | |||
39 | Type II diabetes mellitus | |||
40 | MicroRNAs in cardiomyocyte hypertrophy | |||
41 | Physiological and Pathological Hypertrophy of the Heart | |||
42 | Regulation of toll-like receptor signaling pathway | |||
43 | Osteoclast Signaling | |||
44 | TGF Beta Signaling Pathway | |||
45 | Wnt Signaling Pathway | |||
46 | Wnt Signaling Pathway and Pluripotency | |||
47 | ATM Signaling Pathway |

